大剂量甲氨蝶呤多药联合治疗骨肉瘤的疗效分析  

作　　者：王翌庆[1] 刘云霞[1] 姚勇伟[1] 

机构地区：[1]杭州市第三人民医院肿瘤科,310009

出　　处：《浙江临床医学》2015年第10期1655-1657,共3页Zhejiang Clinical Medical Journal

基　　金：杭州市卫生局项目（2012A0038）

摘　　要：目的 探讨大剂量甲氨蝶呤（HD-MTX）多药联合治疗骨肉瘤患者的化疗有效性及对生存期的影响.方法 回顾性总结63例采用多药大剂量联合化疗方案化疗的骨肉瘤患者的临床资料,观察分析多药大剂量联合化疗治疗骨肉瘤的化疗有效率及对3年生存期随访结果.结果 63例患者经多药大剂量联合化疗方案2周期化疗后总有效率为77.8％,其中肿瘤直径与化疗疗效有显著相关性（P＜0.05）.3年总生存率为67.7％,其中完整化疗4周期后对患者3年总生存率及无进展生存期均产生显著影响（P＜0.05）.结论 含HD-MTX多药联合化疗是有效的,完整的化疗是骨肉瘤综合治疗中不可缺少的重要组成部分.Objective To analysis the efficacy of high dose methotrexate （ HD-MTX ） chemotherapy combined with multi-drug in the treatment of ostetmarcoma patients and evaluate the influence of animal survival. Methods From the clinical data of 63 ostetrnarcoma patients with the treatment of high dose methotrexate （ HD-MTX ） combined with multi-drug, to analysis the efficient and 3- years survival of this kind of chemotherapy. Results Of 63 patients, after 2 cycles of chemotherapy, the total effective rate was 77.8%. There was significant correlation of tumo r size and chemotherapy effect （ P〈0.05 ） . The 3-year overall survival rate was 67.7%. The data of four complete cycles of chemotherapy after surgery in patients has shown that there was significant correlation in the 3-year survival rate and disease-free survival （ P〈0.05 ） . Conclusion The complete chemotherapy is indispensable important component in the comprehensive treatment of osteosarcoma. This paper has shown that HD-MTX combined with multi-drug in treatment of osteosareoma is effective.

关 键 词：大剂量甲氨蝶呤 骨肉瘤 化疗 预后 

分 类 号：R733.71[医药卫生—肿瘤]